Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Doxorubicin Chemoembolization vs Systemic Doxorubicin in Advanced HCC
NCT00079027Phase 3Unknown
- Sponsor
- University Hospitals Birmingham
- Start
- Apr 2004
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of doxorubicin in hepatocellular carcinoma (HCC) (2 arms), sponsored by University Hospitals Birmingham. Primary endpoint: Overall Survival. Status: unknown.
02
Drugs
doxorubicin
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT00079027.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00079027.